Shares in Novartis AG are retreating towards the lower bound of a horizontal trading range. Investors could use the proximity of this support area to initiate new long positions. Investors have an opportunity to buy the stock and target the CHF 88.
Summary
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Strengths
The group's activity appears highly profitable thanks to its outperforming net margins.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
With an enterprise value anticipated at 3.91 times the sales for the current fiscal year, the company turns out to be overvalued.
Disclaimer:
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
